The FTSE 100 ended a difficult week firmly in negative territory on Friday, dragged lower by surging oil prices and growing unease over artificial intelligence investment returns. The blue-chip index closed down
Samsung Biologics has landed a new biologics manufacturing contract worth $262 million with an unnamed European pharmaceutical company, according to a securities filing. The deal, disclosed on Thursday, will run through the
More
Legal and technology teams are facing mounting pressure to align innovation strategies with compliance obligations as artificial intelligence reshapes how multinational organisations operate. A new video series exploring these challenges has launched,
More
London’s blue-chip index pushed steadily higher through Friday’s session, rising 87 points to 10,695 after starting the day just 6 points above Thursday’s close. The FTSE 100 ended a five-day losing streak,
More
Genus (GNS), the animal genetics company listed on the London Stock Exchange, has seen its share price come under pressure, prompting analysts to flag a potential entry point for investors. The stock
More
The full phase 3 dataset from Merck (MRK) and Gilead’s (GILD) failed Trodelvy trial in first-line non-small cell lung cancer has now been made public, raising significant questions for the industry. The
More
Maryland has amended its Maryland Franchise Registration and Disclosure Law, with all changes coming into effect on October 1, 2026, reshaping obligations for franchisors operating in the state. Franchisors registered in Maryland
More
Weil, Gotshal & Manges has suffered a significant departure as Michael Aiello, chair of its roughly 600-lawyer corporate department, heads to rival firm Cravath, Swaine & Moore. Aiello also holds a seat
More
Deere & Company (DE) appears to be trading at a significant discount to its estimated fair value, with analysts suggesting shares may be undervalued by as much as 11%. The agricultural and
More
iShares FTSE 250, the exchange-traded fund tracking mid-cap UK listed companies, has announced a new dividend declaration for its sterling share class. The fund, managed by BlackRock (BLK), is one of the
More
AstraZeneca’s (AZN) camizestrant, branded Etcamah, has failed to demonstrate a statistically significant improvement in a major Phase III breast cancer trial, dealing a blow to the drug’s broader commercial ambitions. The SERENA-4
More